Apixaban anti‐Xa levels in clinical practice: A case report
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16247 ↗Kurz gefasst
Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Sarah Clark und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Department of Pharmacy, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Factor Xa Inhibitors, Pulmonary Embolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Apixaban is a widely used direct oral anticoagulant that is recommended over warfarin therapy for many clinical indications. In patients with atrial fibrillation, dose reductions are recommended for patients with advanced age (≥80 years), low weight (≤60 kg) or elevated serum creatinine (≥1.5 mg/dL), but there is no routine laboratory monitoring necessary for long term‐use. Furthermore, apixaban dose reductions due to renal dysfunction are not recommended when treating acute venous thromboembolism. Apixaban‐calibrated anti‐Xa assays are readily available at some medical centres, and they may be of clinical utility in certain circumstances such as in patients with renal insufficiency, medication adherence assessment, periprocedural planning, extremes in body weight and advanced age. Here, we describe the case of an elderly patient with chronic kidney disease taking apixaban for acute pulmonary embolism. The patient had an unanticipated prolonged apixaban half‐life, with detectable apixaban‐calibrated anti‐Xa levels for >10 days after the last administered dose, which delayed a necessary surgical intervention by >1 week. This case is an example of appropriately using apixaban‐calibrated anti‐Xa levels to guide therapeutic decision making in perioperative planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Department of Pharmacy, Rochester, Minnesota, USA.
- Mayo Clinic Department of Neurology, Rochester, Minnesota, USA.
ORCID-Profile: Sarah Clark, Juan Luis Alcala-Zermeno
Zitieren
APA
Clark, S., & Alcala-Zermeno, J. L. (2024). Apixaban anti‐Xa levels in clinical practice: A case report. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16247
Vancouver
Clark S, Alcala-Zermeno JL. Apixaban anti‐Xa levels in clinical practice: A case report. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16247
BibTeX
@article{Clark2024,
author = {Clark, Sarah and Alcala-Zermeno, Juan Luis},
title = {Apixaban anti‐Xa levels in clinical practice: A case report},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16247}
}
EUVIMED